Key result
Early invasive treatment with thrombolysis and decompressive surgery was associated with a significantly lower long-term DASH-score (mean 5.0) compared to delayed surgery (mean 20.6, p=0.006).
Why the study?
Studies show conflicting results and scarce evidence regarding whether to prefer immediate thrombolysis and decompressive surgery, delayed decompressive surgery, or anticoagulation alone to avoid post-thrombotic syndrome in primary subclavian vein thrombosis.
Does early invasive treatment with thrombolysis and decompressive surgery improve long-term quality of life compared to delayed surgery or anticoagulation alone in patients with primary subclavian vein thrombosis?
Cohort (n=87)
Yes
Does early invasive treatment with thrombolysis and decompressive surgery improve long-term quality of life compared to delayed surgery or anticoagulation alone in patients with primary subclavian vein thrombosis?
Answers are grounded in this paper and cite their sources.
Early invasive treatment with thrombolysis and decompressive surgery for primary subclavian vein thrombosis is associated with significantly better long-term quality of life compared to delayed surgery or anticoagulation alone.
Introduction Primary subclavian vein thrombosis (PSVT) is a rare (2/100,000 per year) disorder, affecting mostly young, active and otherwise healthy individuals. Untreated it can lead to post thrombotic syndrome (PTS) which leaves the patient with a chronic impairment of the arm. Several treatment strategies have been suggested to avoid PTS: immediate thrombolysis and decompressive surgery, delayed decompressive surgery or treatment with anticoagulation alone. Studies show conflicting results, and there is scarce evidence regarding which strategy to prefer. Aim To investigate whether early invasive treatment with thrombolysis and decompressive surgery in patients with PSVT, is associated with improved quality of life compared to delayed decompressive surgery or treatment with anticoagulation alone. Material and methods Quality of life was evaluated in 87 patients treated for PSVT in Stockholm during 2008-2017. Treatment with immediate thrombolysis and surgery (acute group, n=46) was compared to treatment with delayed surgery (chronic group, n=20), and with anticoagulation alone (conservative group, n=21). The patients answered a disease-specific quality of life instrument (Disabilities of the arm, shoulder and hand, DASH) before and after intervention. One-way ANOVA and Post-hoc test was used to identify differences in DASH-score between the treatment groups. A multivariate regression model was used to adjust for potential confounders. Results The acute group had superior outcome with lower DASH-score compared to the chronic group after intervention (p=.006), and compared to the chronic group and conservative group together (p=.0002). No confounders were found. Conclusions Treatment of PSVT with immediate thrombolysis and surgery was related to superior results compared to delayed treatment. Because of the retrospective study design, more research is needed to clarify if causation is present.
No takes yet. Share an insight, caveat, or question.
Lindblom et al. (2025) conducted a cohort in Primary subclavian vein thrombosis (PSVT) (n=87). Early invasive treatment (immediate thrombolysis and decompressive surgery) vs. Delayed decompressive surgery or anticoagulation alone was evaluated on Long-term disease-specific quality of life measured by DASH-score (p=0.006). Early invasive treatment with thrombolysis and decompressive surgery was associated with a significantly lower long-term DASH-score (mean 5.0) compared to delayed surgery (mean 20.6, p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: